[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642350":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":41,"collaborators":20,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":9,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":20,"enrollmentInfo":52,"targetDuration":20,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":65,"whyStopped":20,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"ScinnoHub Pharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SNH-118110","EXPERIMENTAL","Dose escalation: Multiple doses of SNH-118110 Dose expansion: MTD\u002FMAD\u002Frecommended expansion dose",[13],"Drug: SNH-118110 Soft Capsules",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","SNH-118110 Soft Capsules","Participants will continue treatment until progression of disease or the end of the study.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Caicun Zhou, MD","CONTACT","86 021-58822171","CAICUNZHOUDR@TONGJI.EDU.CN",[28],{"facility":29,"status":20,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":20},"The East Hospital Affiliated to Tongji University, Shanghai","Shanghai","Shanghai Municipality","200120","China","CN",{"type":36,"coordinates":37},"Point",[38,39],121.45806,31.22222,{"lat":39,"lon":38},{"type":42,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100642350","phase-1-study-of-snh-118110-in-advanced-solid-tumors-100642350",false,"NCT07649200","Study of SNH-118110 in Advanced Solid Tumors","A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SNH-118110 in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* Ability to understand and voluntarily sign an informed consent form (ICF) prior to any study related procedures.\n* Age ≥ 18 years at the time of signing the ICF.\n* Histologically or cytologically confirmed diagnosis of advanced solid tumors, with the following additional requirements:\n\nDose-escalation phase: Patients with advanced solid tumors harboring a RET gene alteration who have failed standard therapy or are intolerant to standard therapy.\n\nDose-expansion phase:\n\nCohort 1: Locally advanced or metastatic NSCLC with RET gene fusion who have progressed after at least one prior line of therapy, which must include a RET inhibitor.\n\nCohort 2: Treatment-naïve patients with locally advanced or metastatic NSCLC harboring a RET gene fusion.\n\nCohort 3: Other advanced solid tumors harboring RET gene alterations.\n\n* At least one measurable target lesion according to RECIST version 1.1.\n* Documentation of a RET fusion or other activating RET gene alteration (based on a local or central laboratory report).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with no deterioration within the 2 weeks prior to the first dose of study drug.\n* Life expectancy of at least 3 months.\n\nExclusion Criteria:\n\n* Presence of other known oncogenic driver mutations.\n* Prior anti-tumor therapy within specified washout periods prior to first dose (e.g., small molecules, biologics, radiotherapy, major surgery), or failure to recover from clinically significant toxicities.\n* Clinically significant uncontrolled or active conditions, including but not limited to:\n\nInadequate bone marrow, hepatic, or renal function. Significant cardiovascular disease (e.g., uncontrolled hypertension, prolonged QTc, poor ejection fraction, recent thromboembolic events).\n\nActive or uncontrolled infections, bleeding diathesis, or significant pleural\u002Fabdominal\u002Fpericardial effusion requiring intervention.\n\nCentral nervous system metastases unless stable and asymptomatic off steroids.\n\n* Conditions affecting oral drug absorption or gastrointestinal function.\n* History of severe allergic reactions to similar agents.\n* Pregnant or lactating women, or patients with serious concurrent medical or psychiatric conditions that would compromise safety or study compliance.","ALL","18 Years",{"count":53,"type":54},240,"ESTIMATED","INTERVENTIONAL",[57],"PHASE1","This is a multicenter, open-label, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SNH-118110 administered orally. The study consists of a dose-escalation phase and a dose-expansion phase.",[60],"Solid Tumors",[62,63,64],"Advanced Solid Tumors","Medullary Thyroid Cancer","Non-Small Cell Lung Cancer","NOT_YET_RECRUITING","2026-06-11",{"date":68,"type":69},"2026-06-16","ACTUAL",{"date":71,"type":54},"2026-06-26",{"date":73,"type":54},"2029-06-26",{"name":5,"class":6},1]